Seeking Alpha

Delcath Systems, Inc. (DCTH)

  • Wed, Mar. 11, 10:20 AM
    • Delcath Systems (DCTH +0.4%) Q4 results: Revenues: $0.3M (-14.7%); COGS: $0.2M (-33.3%); R&D Expense: $0.7M (-65.0%); SG&A: $2.8M (-24.3%); Operating Loss: ($3.3M) (+40.0%); Net Loss: ($2.9M) (+39.6%); Loss Per Share: ($0.31) (+50.8%).
    • FY2014 results: Revenues: $1.1M (+37.5%); COGS: $0.8M (+166.7%); R&D Expense: $4.3M (-66.1%); SG&A: $15.8M (-23.7%); Operating Loss: ($19.3M) (+41.5%); Net Loss: ($17.4M) (+42.6%); Loss Per Share: ($1.84) (+63.9%); Quick Assets: $20.5M (-34.3%).
    • No guidance given.
    | Comment!
  • Tue, Mar. 10, 4:47 PM
    • Delcath Systems (NASDAQ:DCTH): Q4 EPS of -$0.31 vs. -$0.63 in 4Q13
    • Revenue of $0.29M (-14.7% Y/Y).
    • Press Release
    | Comment!
  • Wed, Feb. 11, 12:45 PM
    | Comment!
  • Wed, Feb. 11, 10:22 AM
    • Thinly-traded nano cap Delcath Systems (DCTH -23.5%) plummets on an 11x surge in volume in response to its public offering of 2.460M shares of common stock and warrants to purchase up to 1.107M shares of common stock at a combined price of $1.15. The exercise price of the warrants is $1.38. Closing date is February 17.
    • Net proceeds of ~$2.4M will fund clinical trials, ongoing operations and general corporate purposes.
    | Comment!
  • Wed, Feb. 11, 9:13 AM
  • Fri, Jan. 9, 12:47 PM
  • Nov. 5, 2014, 4:09 PM
    • Delcath Systems (NASDAQ:DCTH): Q3 EPS of -$0.48
    • Revenue of $217K (+201.4% Y/Y)
    • Press Release
    | Comment!
  • Sep. 17, 2014, 1:38 PM
    • Citing its inability to meet with Delcath Systems' (DCTH -6.1%) management and BOD, among other issues, shareholder Linkedto Partners withdraws its $3 per share bid and sells its stake in the company.
  • Sep. 15, 2014, 5:17 PM
    • Delcath Systems (DCTH +3.1%) announces a management reorganization. Gabriel Leung steps down as Chairman of the Board but will continue as a board member. Board member Dr. Roger G. Stoll appointed Executive Chairman.
    • Interim Co-President and interim Co-CEO Dr. Jennifer Simpson appointed interim President and interim CEO.
    • Interim Co-President  and interim Co-CEO Dr. Graham Miao will leave the company at the end of September.
    • VP, Controller and Principal Accounting Officer Barbra Keck appointed Principal Financial Officer.
    | Comment!
  • Sep. 15, 2014, 10:42 AM
    • Shareholder Linkedto Partners says two NASDAQ-traded firms have approached it about a merger or buyout of Delcath Systems (DCTH +4.3%).
    • Linkedto has the support of 4.9% of DCTH shares. It is calling for a sale of the company as a means to unlock shareholder value. Last week, it upped its non-binding offer to $3.00 per share.
    | Comment!
  • Sep. 11, 2014, 4:31 PM
    • Activist shareholder Linkedto Partners says it and its allies now control 4.8% of Delcath Systems (DCTH +0.4%) common stock. In conjunction with recruiting support, it recently sent communications to each board member regarding the company's underperformance and the need for a sale.
    • Linkedto also states that it has become aware that the BOD has had discussions with potential acquirers, including Medtronic, over the past few years about a potential transaction.
    • The market remains unconvinced. Shares were up a fraction today on turnover of only 15.5K shares.
  • Sep. 9, 2014, 10:40 AM
    • Delcath Systems (DCTH +0.4%) shareholder Linkedto Partners raises its unsolicited non-binding offer for the company to $3.00 per share. Yesterday, its offer was $2.90. This past Friday it was $2.85. At this rate, Delcath can continue to ignore Linkedto's overtures and expect to get a $6.00 offer by mid-October.
    • Linkedto controls less than 1% of the stock so it is highly unlikely to make any progress until it can corral a large enough stake to get management's attention.
    • Considering DCTH's current price of $2.38 (unchanged), the market is not regarding the action seriously either.
    | 1 Comment
  • Sep. 5, 2014, 10:43 AM
    • Delcath Systems (DCTH +1.3%) shareholder Linkedto Partners makes an unsolicited non-binding $2.85 per share offer for the company. The offer represents a 19.2% premium over the current price of $2.39.
  • Sep. 3, 2014, 2:07 PM
    • Shares of thinly-traded nano cap Delcath Systems (DCTH -3.5%) ease up today on increased volume. Shares rose 7% yesterday after activist shareholder Linkedto Partners called for management to cut their hefty salaries in order to save money and pursue an immediate sale of the firm considering its substantial cash burn and scant revenues.
    • Whether or not management listens to Linedto Partners is unknown. Its position is only 77K shares which represents a modest 0.8% stake.
  • Aug. 8, 2014, 1:04 PM
    • Delcath Systems (DCTH -2%) Q2 results: Revenues: $251K; Operating Loss: ($5.9M) (+44.2%); Net Loss: ($4.6M) (+16.1%); Loss Per Share: ($0.52) (+42.9%); Quick Assets: $27.3M (-12.5%).
    • No financial guidance given.
    | 1 Comment
  • Aug. 6, 2014, 9:50 PM
    • Delcath Systems (DCTH +6.2%) Q2 results: Total Revenues: $251K; Operating Expenses: $6.1M (-40.8%); Operating Loss: ($5.9M) (+44.3%); Net Loss: ($4.6M) (+16.1%); Loss Per Share: ($0.52) (+42.9%); Quick Assets: $27.3M (-12.5%).
    • No guidance given.
    | Comment!
Visit Seeking Alpha's
DCTH vs. ETF Alternatives
Company Description
Delcath Systems Incis a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver.